IMMUSE is a patented paraprobiotic backed by over 25 studies and 11 human clinical trials and has been shown to provide the most comprehensive immune support with unmatched formulation benefits
2020 and 2021 have shown us that immune health is no longer a seasonal need. Immune health and overall wellness are starting to become synonymous terms for consumers, however, the category has seen limited innovation over the last several years. With increasing demand, consumers are looking for innovative ingredients and delivery formats to balance their immune system. Kyowa Hakko, in partnership with Kirin, is pleased to introduce IMMUSE.
Discovered by researchers at Kirin, IMMUSE is a patented paraprobiotic that stimulates pDCs (plasmacytoid dendritic cells), a rare set of cells that spur multiple essential immune cells into action for a more well-rounded and thorough immune response.
Nearly all immune support supplements, like conventional probiotics and elderberry, mainly target NK cells, providing limited support. Unlike those ingredients, IMMUSE stimulates pDC cells, often described as the leader of the immune system. pDC cells straddle between the innate and adaptive functions of the immune system, playing a pivotal role by activating Killer T, NK, Helper T, and B cells.
Additionally, the formulation benefits of IMMUSE are unmatched. Since it is a paraprobiotic, there is no need to worry about viability. IMMUSE is also stable at room temperature and provides broad-ranging formulation flexibility.
Download the IMMUSE product brochure to learn more about this patented paraprobiotic.